Richard A. Larson to Stem Cell Transplantation
This is a "connection" page, showing publications Richard A. Larson has written about Stem Cell Transplantation.
Connection Strength
0.564
-
Myelodysplasia: when to treat and how. Best Pract Res Clin Haematol. 2006; 19(2):293-300.
Score: 0.249
-
Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007; 453-9.
Score: 0.067
-
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
Score: 0.060
-
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14925-30.
Score: 0.050
-
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.
Score: 0.041
-
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84.
Score: 0.026
-
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
Score: 0.024
-
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2007 Aug 01; 25(22):3337-43.
Score: 0.017
-
End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6.
Score: 0.016
-
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood. 2004 Jun 01; 103(11):4373-4.
Score: 0.014